Shell Midstream Partners, L.P. Announces Private Placement

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Shell Midstream Partners, L.P. Announces Private Placement of Common Units

Houston, May 13, 2015 (GLOBE NEWSWIRE) -- Shell Midstream Partners, L.P. (NYSE: SHLX) today announced the execution of an agreement with a group of institutional investors to sell 7,692,308 common units representing limited partner interests in a private placement. Shell Midstream Partners expects to receive gross proceeds of $300 million.  The proceeds will be used to partially fund the acquisition of additional ownership interests in Zydeco Pipeline Company, LLC and Colonial Pipeline Company from Shell Pipeline Company LP. The private placement is expected to close May 18, 2015 in conjunction with the closing of the acquisition, both of which are subject to customary closing conditions.

The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements of the Securities Act and applicable state laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities described herein.

# # #

About Shell Midstream Partners, L.P. Shell Midstream Partners is a fee-based, growth-oriented midstream master limited partnership formed by Royal Dutch Shell to own, operate, develop and acquire pipelines and other midstream assets. Shell Midstream Partners' assets consist of interests in entities that own crude oil and refined products pipelines serving as key infrastructure to transport growing onshore and offshore crude oil production to Gulf Coast refining markets and to deliver refined products from those markets to major demand centers.

FORWARD-LOOKING STATEMENTS This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Shell Midstream Partners, L.P. to market risks and statements expressing management's expectations, beliefs, estimates, forecasts, projections and assumptions. You can identify our forward-looking statements by words such as "anticipate", "believe", "estimate", "expect", "forecast", "goals", "objectives", "outlook", "intend", "plan", "predict", "project", "risks", "schedule", "seek", "target", "could", "may", "will", "should" or "would" or other similar expressions that convey the uncertainty of future events or outcomes. In accordance with "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, these statements are accompanied by cautionary language identifying important factors, though not necessarily all such factors, which could cause future outcomes to differ materially from those set forth in forward-looking statements. In particular, expressed or implied statements concerning future actions, conditions or events, future operating results or the ability to generate sales, income or cash flow or to make distributions are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve risks, uncertainties and assumptions. Future actions, conditions or events and future results of operations may differ materially from those expressed in these forward-looking statements. Forward-looking statements speak only as of the date of this press release, May 13, 2015, and we disclaim any obligation to update such statements for any reason, except as required by law. All forward-looking statements contained in this document are expressly qualified in their entirety by the cautionary statements contained or referred to in this paragraph. Many of the factors that will determine these results are beyond our ability to control or predict. These factors include the risk factors described in Part I, Item 1A.  "Risk Factors" in our Annual Report on Form 10-K filed with the SEC on March 25, 2015. If any of those risks occur, it could cause our actual results to differ materially from those contained in any forward-looking statement. Because of these risks and uncertainties, you should not place undue reliance on any forward-looking statement.

Investor Relations: (832) 337-2034 Media Relations: (713) 241-4544

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 356

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 371

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 150

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 347

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 204

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 309

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 238

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 177

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 243

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading

Top 5 Most Recently Viewed Articles

Air Canada Navigates Operational Challenges Amid Storms

Updated Category News Views 205

Air Canada's Operational Challenges and Responses Air Canada has recently faced significant operational hurdles due to severe winter weather and an aircraft incident impacting its Toronto Pearson international hub. These challenges have necessitated a comprehensive update from the airline about its current status and ongoing recovery efforts. Recent Weather Impact on...

Continue Reading
Insight into Melexis' Ongoing Share Buy-Back Strategy

Updated Category News Views 128

Melexis Enhances Shareholder Value Through a Strategic Buyback Melexis, a leader in the semiconductor industry, has been actively engaging in a strategic share buy-back program aimed at bolstering shareholder value. This initiative, first announced on December 10, 2024, reflects the company's commitment to enhancing its stock's performance while also optimizing its...

Continue Reading
Value Line, Inc. Launches New Share Repurchase Initiative

Updated Category News Views 220

Value Line, Inc. Announces Stock Repurchase Program Value Line, Inc. (NASDAQ: VALU) recently revealed an exciting development for its shareholders: the Board of Directors has approved a share repurchase program that allows for the buyback of up to $2,000,000 worth of shares. This program comes into effect immediately and marks a significant move that replaces the previous...

Continue Reading
IsoEnergy Expands Stake in Premier American Uranium Inc. Assets

Updated Category News Views 154

IsoEnergy Enhances Investment in Premier American Uranium Inc. IsoEnergy Ltd. (NYSE American: ISOU) (TSX: ISO) has recently expanded its investment in Premier American Uranium Inc. by acquiring a significant number of common shares and warrants. This strategic move further establishes IsoEnergy’s commitment to capitalizing on the promising uranium market amid increasing...

Continue Reading
Texas Attorney General Takes Action Against Insulin Price Fixing

Updated Category News Views 70

Texas Attorney General's Lawsuit Against Insulin Price Fixing Texas Attorney General Ken Paxton has taken significant action by filing a lawsuit against several prominent insulin manufacturers and pharmacy benefit managers (PBMs). The lawsuit highlights allegations of a conspiracy to inflate insulin prices, affecting countless patients who rely on this vital medication....

Continue Reading